Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6282854 | 0.95 | KDM4E (0.41) | SOAT1KDM4EMEN1KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6280105 | 0.81 | SOAT1 (0.53) | SOAT1MEN1KMT2ADRD2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5623338 | 0.79 | ALDH1A1 (0.40) | SOAT1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6280351 | 0.76 | SOAT1 (0.74) | SOAT1 | |
| Trifluoroacetic Acid SCHEMBL1705470 | 0.75 | SOAT1 (0.52) | SOAT1MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL6280359 | 0.74 | SOAT1 (0.75) | SOAT1MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL6282990 | 0.73 | SOAT1 (0.48) | SOAT1KDM4EDRD2DRD3ALDH1A1 | |
| SCHEMBL6282311 | 0.73 | SOAT1 (0.67) | SOAT1 | |
| SCHEMBL6283922 | 0.72 | SOAT1 (0.68) | SOAT1 | |
| SCHEMBL5623132 | 0.72 | TMEM97 (0.39) | SOAT1KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969711-B2 | Cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| EP-0987254-B1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | KOWA CO (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | KOWA COMPANY, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-0987254-A1 | NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038987-A1 | Novel cyclic diamine compounds and medicine containing the same | LCAT, ACAT2, ACAT1 | SOAT1 5/4885KDM4E 1460/4885MEN1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.